Corvus Pharmaceuticals Inc

NASDAQ:CRVS   3:59:43 PM EDT
3.90
-0.04 (-1.01%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Corvus Pharmaceuticals, Inc. Stock, NASDAQ:CRVS

863 MITTEN ROAD, SUITE 102, BURLINGAME, CA 94010
United States of America
Phone: (650) 900-4520
Number of Employees: 49

Description

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that plan to initiate a Phase 1/1b clinical trial for adenosine, an immune checkpoint. The company also develops a product candidate, an anti-CD73 monoclonal antibody that inhibits the production of adenosine. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.